Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SAM LERMAN

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1932112661
CMS profile
313984
Location
HOLLYWOOD, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$8,576.99

102 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SAM LERMAN

NPI 1932112661 · CMS profile ID 313984

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

HOLLYWOOD, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1932112661?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SAM LERMAN, NPI 1932112661, CMS profile ID 313984. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932112661?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). SAM LERMAN, NPI 1932112661, CMS profile ID 313984. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932112661?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
SAM LERMAN, NPI 1932112661, CMS profile ID 313984, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1932112661?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

102 matching records · $8,576.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 102 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 102.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $6.4807/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188252995 CMS
Neurocrine BioSciences, Inc. $27.5907/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242995633 CMS
Novartis Pharmaceuticals Corporation $25.3107/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200601511 CMS
Senseonics, Incorporated $400.0007/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1249761560 CMS
ABBVIE INC. $19.6706/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202291399 CMS
Sequel Med Tech, LLC $14.1206/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243741556 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.5406/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222730978 CMS
Amneal Pharmaceuticals LLC $18.7506/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1220540663 CMS
Novartis Pharmaceuticals Corporation $27.1906/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200601509 CMS
Novo Nordisk Inc $19.4906/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188663230 CMS
Amgen Inc. $22.7406/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228352106 CMS
SANOFI-AVENTIS U.S. LLC $22.9206/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233290616 CMS
Esperion Therapeutics, Inc. $26.4106/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243965878 CMS
Novartis Pharmaceuticals Corporation $22.0905/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200601505 CMS
Novartis Pharmaceuticals Corporation $1.4405/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200601507 CMS
Lilly USA, LLC $27.8705/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186866801 CMS
Dexcom, Inc. $19.1705/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250520334 CMS
Lilly USA, LLC $21.1605/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186888337 CMS
Amneal Pharmaceuticals LLC $15.5705/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1220540661 CMS
Novo Nordisk Inc $22.7205/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188244269 CMS
Novo Nordisk Inc $21.9304/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189128123 CMS
Xeris Pharmaceuticals, Inc. $24.0904/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250174912 CMS
Tandem Diabetes Care, Inc. $23.9104/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241264418 CMS
Lilly USA, LLC $17.7804/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186933458 CMS
Senseonics, Incorporated $400.0004/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1249761558 CMS
Amgen Inc. $16.4904/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228352110 CMS
Xeris Pharmaceuticals, Inc. $20.7703/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250174908 CMS
RECORDATI_RARE_DISEASES_INC. $28.5503/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181718799 CMS
Lilly USA, LLC $20.1303/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186921230 CMS
Novo Nordisk Inc $22.5403/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188316579 CMS
Corcept Therapeutics $27.3603/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214155289 CMS
Dexcom, Inc. $24.0803/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250520330 CMS
Novartis Pharmaceuticals Corporation $10.8803/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200601493 CMS
KYOWA KIRIN, INC. $29.9603/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222092767 CMS
Tandem Diabetes Care, Inc. $116.2203/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241264421 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.2902/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222730976 CMS
Xeris Pharmaceuticals, Inc. $23.4602/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250174906 CMS
Amgen Inc. $15.2002/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228352112 CMS
Novo Nordisk Inc $19.7402/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189166261 CMS
Sequel Med Tech, LLC $27.1502/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243741548 CMS
Xeris Pharmaceuticals, Inc. $19.9202/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250174910 CMS
Novartis Pharmaceuticals Corporation $23.4002/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200601495 CMS
Ascendis Pharma Endocrinology Inc $25.1402/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237032811 CMS
Senseonics, Incorporated $400.0001/30/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1249761556 CMS
ABBVIE INC. $15.6601/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202291397 CMS
Corcept Therapeutics $23.9901/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214155287 CMS
Lilly USA, LLC $16.7101/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186909324 CMS
RECORDATI_RARE_DISEASES_INC. $20.1501/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181718797 CMS
Mannkind Corporation $24.2201/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250877977 CMS
Novo Nordisk Inc $23.8901/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189137886 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,315.16 194
PY2020 $4,112.23 76
PY2021 $2,227.27 140
PY2022 $2,992.76 127
PY2023 $2,440.78 113
PY2024 $1,812.79 93
PY2025 $8,576.99 102

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $335,590.13 36
PY2024 Recipient $9,428.00 1
PY2024 Principal investigator $178,229.35 17
PY2023 Recipient $1,199.93 7
PY2023 Principal investigator $239,468.76 16
PY2022 Recipient $5,353.00 1
PY2022 Principal investigator $283,771.68 351
PY2021 Principal investigator $348,095.66 599
PY2020 Recipient $190.23 1
PY2020 Principal investigator $217,899.99 46
PY2019 Principal investigator $218,165.40 94

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $10,440.00 12/31/2025 Non-covered Recipient Entity
CENTER FOR DIABETES AND ENDOCRINE CARE
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202532819
Principal investigator 1 Senseonics, Incorporated $345.00 12/18/2025 Non-covered Recipient Entity
ADVARRA
Senseonics CTP-0039 No dispute reported 06/30/2026 1249851791
Principal investigator 1 Senseonics, Incorporated $618.75 12/04/2025 Non-covered Recipient Entity
THE CENTER FOR DIABETES AND ENDOCRINE CARE
Senseonics CTP-0039 No dispute reported 06/30/2026 1249853129
Principal investigator 1 Senseonics, Incorporated $31.25 12/04/2025 Non-covered Recipient Entity
THE CENTER FOR DIABETES AND ENDOCRINE CARE
Senseonics CTP-0039 No dispute reported 06/30/2026 1249853131
Principal investigator 1 Senseonics, Incorporated $1,000.00 12/04/2025 Non-covered Recipient Entity
THE CENTER FOR DIABETES AND ENDOCRINE CARE
Senseonics CTP-0039 No dispute reported 06/30/2026 1249853133
Principal investigator 1 Senseonics, Incorporated $500.00 12/04/2025 Non-covered Recipient Entity
THE CENTER FOR DIABETES AND ENDOCRINE CARE
Senseonics CTP-0039 No dispute reported 06/30/2026 1249853135
Principal investigator 1 ABBVIE INC. $10,844.40 11/05/2025 Non-covered Recipient Entity
JELLINGER AND LERMAN MD PA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202522027
Principal investigator 1 ABBVIE INC. $4,759.20 10/09/2025 Non-covered Recipient Entity
JELLINGER AND LERMAN MD PA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202516421
Principal investigator 1 Siemens Medical Solutions USA, Inc. $7,234.00 09/11/2025 Non-covered Recipient Entity
Center For Diabetes And Endocrine Care
Specimen Collection for Siemens Thyroid Antibody Assays No dispute reported 06/30/2026 1173556360
Principal investigator 1 ABBVIE INC. $10,533.60 09/04/2025 Non-covered Recipient Entity
JELLINGER AND LERMAN MD PA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509794
Principal investigator 1 ABBVIE INC. $12,525.60 08/06/2025 Non-covered Recipient Entity
JELLINGER AND LERMAN MD PA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202503155
Principal investigator 1 ABBVIE INC. $3,981.60 07/02/2025 Non-covered Recipient Entity
JELLINGER AND LERMAN MD PA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202494847
Principal investigator 1 ABBVIE INC. $20,376.00 06/03/2025 Non-covered Recipient Entity
JELLINGER AND LERMAN MD PA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202487813
Principal investigator 1 ABBVIE INC. $11,496.00 05/07/2025 Non-covered Recipient Entity
JELLINGER AND LERMAN MD PA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202483367
Principal investigator 1 ABBVIE INC. $1,886.40 04/03/2025 Non-covered Recipient Entity
JELLINGER AND LERMAN MD PA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202468818
Principal investigator 1 Amgen Inc. $2,209.00 03/22/2025 Non-covered Recipient Entity
JELLINGER AND LERMAN MD PA DBA THE CENTER FOR DIABETES AND ENDOCRINE CARE
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke No dispute reported 06/30/2026 1246643119
Principal investigator 1 Eli Lilly and Company $4.26 03/13/2025 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187890936
Principal investigator 1 ABBVIE INC. $7,657.20 03/07/2025 Non-covered Recipient Entity
JELLINGER AND LERMAN MD PA
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202461608
Principal investigator 1 Eli Lilly and Company $46.69 02/18/2025 Non-covered Recipient Entity
JELLINGER AND LERMAN MD PA DBA CNTR FOR DIABETES
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187883768
Principal investigator 1 Eli Lilly and Company $86,499.00 02/18/2025 Non-covered Recipient Entity
JELLINGER AND LERMAN MD PA DBA CNTR FOR DIABETES
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187883770
Principal investigator 1 Eli Lilly and Company $2,144.42 02/13/2025 Non-covered Recipient Entity
JELLINGER AND LERMAN MD PA DBA CNTR FOR DIABETES
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187886028
Principal investigator 1 ABBVIE INC. $9,102.00 02/06/2025 Non-covered Recipient Entity
JELLINGER AND LERMAN MD PA
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202448563
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,814.38 01/28/2025 Non-covered Recipient Entity
JELLINGER NOVAK ENDOCRINOLOGY DIABETES CONSULTANTS
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190299580
Principal investigator 1 Novartis Pharmaceuticals Corporation $40,002.69 01/27/2025 Non-covered Recipient Entity
CENTER FOR DIABETES AND ENDOCRINE CARE
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190302701
Principal investigator 1 Eli Lilly and Company $39,953.00 01/21/2025 Non-covered Recipient Entity
JELLINGER AND LERMAN MD PA DBA CNTR FOR DIABETES
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187886026
Principal investigator 1 Senseonics, Incorporated $1,659.38 01/09/2025 Non-covered Recipient Entity
THE CENTER FOR DIABETES AND ENDOCRINE CARE
Senseonics CTP-0034 No dispute reported 06/30/2026 1249853111
Principal investigator 1 Senseonics, Incorporated $125.00 01/09/2025 Non-covered Recipient Entity
THE CENTER FOR DIABETES AND ENDOCRINE CARE
Senseonics CTP-0034 No dispute reported 06/30/2026 1249853113
Principal investigator 1 Senseonics, Incorporated $1,159.38 01/09/2025 Non-covered Recipient Entity
THE CENTER FOR DIABETES AND ENDOCRINE CARE
Senseonics CTP-0034 No dispute reported 06/30/2026 1249853115
Principal investigator 1 Senseonics, Incorporated $125.00 01/09/2025 Non-covered Recipient Entity
THE CENTER FOR DIABETES AND ENDOCRINE CARE
Senseonics CTP-0034 No dispute reported 06/30/2026 1249853117
Principal investigator 1 Senseonics, Incorporated $2,509.38 01/09/2025 Non-covered Recipient Entity
THE CENTER FOR DIABETES AND ENDOCRINE CARE
Senseonics CTP-0034 No dispute reported 06/30/2026 1249853119
Principal investigator 1 Senseonics, Incorporated $125.00 01/09/2025 Non-covered Recipient Entity
THE CENTER FOR DIABETES AND ENDOCRINE CARE
Senseonics CTP-0034 No dispute reported 06/30/2026 1249853121
Principal investigator 1 Senseonics, Incorporated $2,409.38 01/09/2025 Non-covered Recipient Entity
THE CENTER FOR DIABETES AND ENDOCRINE CARE
Senseonics CTP-0034 No dispute reported 06/30/2026 1249853123
Principal investigator 1 Senseonics, Incorporated $62.50 01/09/2025 Non-covered Recipient Entity
THE CENTER FOR DIABETES AND ENDOCRINE CARE
Senseonics CTP-0034 No dispute reported 06/30/2026 1249853125
Principal investigator 1 Senseonics, Incorporated $2,000.00 01/09/2025 Non-covered Recipient Entity
THE CENTER FOR DIABETES AND ENDOCRINE CARE
Senseonics CTP-0034 No dispute reported 06/30/2026 1249853127
Principal investigator 1 Amgen Inc. $30,928.27 01/03/2025 Non-covered Recipient Entity
JELLINGER AND LERMAN MD PA DBA THE CENTER FOR DIABETES AND ENDOCRINE CARE
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246643117
Principal investigator 1 ABBVIE INC. $3,482.40 01/02/2025 Non-covered Recipient Entity
JELLINGER AND LERMAN MD PA
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202434950